AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
PHASE1CompletedINTERVENTIONAL
Enrollment
68
Participants
Timeline
Start Date
July 31, 2006
Primary Completion Date
January 31, 2013
Conditions
Male Breast CancerRecurrent Breast CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerRecurrent Renal Cell CancerStage IV Breast CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity CancerStage IV Renal Cell CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG
AFP464
Given IV
OTHER
pharmacological study
Correlative studies
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
55905
Mayo Clinic, Rochester
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00348699 - AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter